Treatment of Prostate Cancer With Firmagon®

United Clinic Management

Status: Completed

Conditions: Prostate Cancer

Treatments: Drug: Degarelix

Study type: Observational

Funder types: Industry

Identifiers

NCT01710098

UCM12-01

Details and patient eligibility

About

How are testosterone levels of patients with prostate cancer under treatment with Firmagon® changing.

Former studies showed a quick fall of testosterone levels after start of therapy with Firmagon® and a quick recovery when therapy is stopped. The investigators want to prove this in a normal outpatient urologist setting. Furthermore data is collected to prove the adherence to the German S3-Guideline for the treatment of prostate cancer.

Enrollment: 100 patients

Sex: Male

Ages: 18 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• advanced hormone-dependent prostate cancer with no other previous hormone therapy for whom - irrespectively of this NIS -the use of Firmagon® is intended

Exclusion criteria

• contraindication for Degarelix

Trial design

100 participants in 1 patient group

Degarelix

Description:

adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year

Treatment:

Drug: Degarelix